CVS Health (CVS) – Analysts’ Weekly Ratings Changes

CVS Health (NYSE: CVS) has recently received a number of price target changes and ratings updates:

• 6/1/2026 – CVS Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $113.00 price target on the stock.
• 6/1/2026 – CVS Health had its price target raised by Truist Financial Corporation from $102.00 to $108.00. They now have a “buy” rating on the stock.
• 5/26/2026 – CVS Health had its price target raised by Barclays PLC from $101.00 to $106.00. They now have an “overweight” rating on the stock.
• 5/20/2026 – CVS Health had its price target raised by Mizuho from $102.00 to $110.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – CVS Health had its price target raised by Argus from $90.00 to $104.00. They now have a “buy” rating on the stock.
• 5/14/2026 – CVS Health had its price target raised by Morgan Stanley from $93.00 to $106.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – CVS Health had its price target raised by JPMorgan Chase & Co. from $101.00 to $111.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – CVS Health had its price target raised by Sanford C. Bernstein from $94.00 to $106.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – CVS Health had its price target raised by TD Cowen from $105.00 to $110.00. They now have a “buy” rating on the stock.
• 5/11/2026 – CVS Health had its price target raised by TD Cowen from $105.00 to $110.00. They now have a “buy” rating on the stock.
• 5/9/2026 – CVS Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/8/2026 – CVS Health had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 5/8/2026 – CVS Health had its price target raised by Wells Fargo & Company from $102.00 to $103.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – CVS Health had its price target raised by Royal Bank Of Canada from $93.00 to $107.00. They now have an “outperform” rating on the stock.
• 5/7/2026 – CVS Health had its price target raised by Barclays PLC from $93.00 to $101.00. They now have an “overweight” rating on the stock.
• 5/7/2026 – CVS Health had its price target raised by UBS Group AG from $97.00 to $100.00. They now have a “buy” rating on the stock.
• 5/7/2026 – CVS Health had its price target raised by Truist Financial Corporation from $98.00 to $102.00. They now have a “buy” rating on the stock.
• 5/7/2026 – CVS Health had its price target raised by DA Davidson from $80.00 to $100.00. They now have a “buy” rating on the stock.
• 5/7/2026 – CVS Health had its price target raised by Deutsche Bank Aktiengesellschaft from $88.00 to $92.00. They now have a “buy” rating on the stock.
• 5/5/2026 – CVS Health had its price target raised by HSBC Holdings plc from $83.00 to $85.00. They now have a “hold” rating on the stock.
• 4/15/2026 – CVS Health had its price target raised by Robert W. Baird from $92.00 to $94.00. They now have an “outperform” rating on the stock.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s dividend payout ratio is 117.18%.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.